Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $463,000.

  • Fulcrum Therapeutics' Other Accumulated Expenses fell 41.00% to $236,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $236,000, marking a year-over-year decrease of 41.00%. This contributed to the annual value of $463,000 for FY2024, which is 16.92% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Other Accumulated Expenses stood at $463,000 for FY2024, which was up 16.92% from $396,000 recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Other Accumulated Expenses peaked at $463,000 during FY2024, and registered a low of $44,000 during FY2020.
  • For the 3-year period, Fulcrum Therapeutics' Other Accumulated Expenses averaged around $321,333, with its median value being $396,000 (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Other Accumulated Expenses decreased by 10.20% in 2020, and later surged by 277.14% in 2023.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Other Accumulated Expenses stood at $44,000 in 2020, then spiked by 68.18% to $74,000 in 2021, then spiked by 41.89% to $105,000 in 2022, then soared by 277.14% to $396,000 in 2023, then grew by 16.92% to $463,000 in 2024.